Navigation Links
PDI Announces Contract Extension With Revenue Value of Approximately $23 Million
Date:4/4/2011

PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading provider of integrated promotional outsource services to health care companies, today announced the extension of a contract sales engagement with an existing Top 5 global pharmaceutical client. The extension began April 1 and will run for the balance of 2011. This program is expected to generate total revenue to PDI of approximately $23 million.

Under the program, PDI will provide the client with a dedicated sales team that will call on primary care physicians.

"The extension of this engagement with a major client reaffirms the high return on investment and strategic flexibility that PDI is able to consistently provide to our customers," said Nancy Lurker, Chief Executive Officer of PDI, Inc. "As a company, we remain intensely focused on delivering optimal value to our customers by developing and deploying the most effective resources and technologies for communicating with physicians and other health care providers."

About PDI

PDI, with its interactive digital agency Group DCA, is a leading provider of integrated multichannel promotional outsource services to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, innovative multichannel promotional solutions, and sales and marketing expertise. For more information, please visit the company's website at http://www.pdi-inc.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive
'/>"/>

SOURCE PDI, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
(Date:8/31/2015)...  DICOM Grid,  the #1 medical image exchange ... as a semifinalist for a Minnie award for ... are sponsored by Auntminnie.com, a comprehensive community website ... imaging industry.  Since 1999, the "Minnies" have provided ... contributions of their peers. Nominations are made by ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
(Date:9/1/2015)... , ... September 01, 2015 , ... Royal River Natural ... study that followed men and women for 19 years and found that, among those ... not take multivitamins. , The report is part of the September 2015 issue of ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... D.O., has joined its medical management team as an Associate Medical Director. ... sizes and types in the U.S. and abroad. , Dr. Nelson has ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Two of Washington ... cultural relations through food and dining. , Recently named “the next big thing” ... Diotaiuti are known for telling the whole story behind food and reclaiming culinary traditions ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, tax, ... named a “Best of the Best” firm in the U.S., as well as being ... of the Best” in the U.S., selected exclusively on performance in specific areas of ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Kit is now available. With the Connectivity Kit, EasySampler data is ... jacketed lab reactor control experiment, on a touchscreen platform. , EasySampler fully ...
Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... Northeast, and boys are at higher risk than girls, study ... sweeping government study of childhood cancers has found numerous differences ... and where he or she lives in the United States. ... cancers, the researchers found, and youngsters in the Northeast were ...
... June 2 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) ... its lead anticancer agent Cloretazine(R) (VNP40101M) in,combination with cytarabine ... had been presented at the 44th Annual Meeting of,the ... The Phase III trial started in March 2005 ...
... (ASCO) ... Annual Meeting -, IRVINE, Calif., June 2 ... an analysis from the,Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The results,suggest ... reduction in the risk of death in newly diagnosed,patients with metastatic osteosarcoma, ...
... Marketing and, Communications Professionals for Inspiring Tales of Patient and ... ... EL SEGUNDO, Calif., June 2 DaVita Inc., a leading,provider ... failure (CKD), today announced that the company,s internal,publication, DaVita Magazine: Stories ...
... BETHESDA, Md., June 2 /Xinhua-PRNewswire/ -- Chindex ... Western healthcare,services and products in the People,s ... division, United Family Healthcare (UFH), responded to,the ... personnel,and other in- kind donations., Roberta ...
... the overall rate of high school baseball-related injuries has ... injuries that occur has increased, according to a new ... Research and Policy (CIRP) of The Research Institute at ... estimated 132,000 high school baseball-related injuries occurred with an ...
Cached Medicine News:Health News:U.S. Childhood Cancers Vary by Sex, Region 2Health News:U.S. Childhood Cancers Vary by Sex, Region 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 2Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 3Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 5Health News:DaVita Magazine Takes Home Two Prestigious Hermes Creative Awards 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 3Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 4Health News:Injuries to high school baseball players becoming more serious 2
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... The 45° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
Medicine Products: